{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:17:03Z","timestamp":1793776623031,"version":"4.6.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T00:00:00Z","timestamp":1613952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T00:00:00Z","timestamp":1613952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004410","name":"European Molecular Biology Organization","doi-asserted-by":"publisher","award":["ALTF 263\u20102018"],"award-info":[{"award-number":["ALTF 263\u20102018"]}],"id":[{"id":"10.13039\/100004410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1038\/s41591-021-01232-w","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T12:02:36Z","timestamp":1613995356000},"page":"491-503","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":234,"title":["Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing"],"prefix":"10.1038","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9061-7287","authenticated-orcid":false,"given":"Yael C.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mor","family":"Zada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9683-4103","authenticated-orcid":false,"given":"Shuang-Yin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chamutal","family":"Bornstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyal","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Moshe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoguo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shir","family":"Shlomi-Loubaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe E.","family":"Gatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chamutal","family":"Gur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Lavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1722-4807","authenticated-orcid":false,"given":"Chezi","family":"Ganzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0212-2135","authenticated-orcid":false,"given":"Efrat","family":"Luttwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeni","family":"Chubar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ory","family":"Rouvio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8390-064X","authenticated-orcid":false,"given":"Iuliana","family":"Vaxman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oren","family":"Pasvolsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouna","family":"Ballan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Tadmor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anatoly","family":"Nemets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osnat","family":"Jarchowcky-Dolberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Shvetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meirav","family":"Laiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Shpilberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najib","family":"Dally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irit","family":"Avivi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assaf","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2968-877X","authenticated-orcid":false,"given":"Ido","family":"Amit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,22]]},"reference":[{"key":"1232_CR1","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3816\/CLM.2009.n.056","volume":"9","author":"RA Kyle","year":"2009","unstructured":"Kyle, R. A. & Rajkumar, S. V. Treatment of multiple myeloma: a comprehensive review. Clin. Lymphoma Myeloma 9, 278\u2013288 (2009).","journal-title":"Clin. Lymphoma Myeloma"},{"key":"1232_CR2","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo, A. & Anderson, K. Multiple myeloma. N. Engl. J. Med. 364, 1046\u20131060 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1232_CR3","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/bloodadvances.2019000432","volume":"3","author":"Y Yan","year":"2019","unstructured":"Yan, Y. et al. The impact of response kinetics for multiple myeloma in the era of novel agents. Blood Adv. 3, 2895\u20132904 (2019).","journal-title":"Blood Adv."},{"key":"1232_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40265-017-0841-y","volume":"78","author":"IS Nijhof","year":"2018","unstructured":"Nijhof, I. S., van de Donk, N. W. C. J., Zweegman, S. & Lokhorst, H. M. Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update. Drugs 78, 19\u201337 (2018).","journal-title":"Drugs"},{"key":"1232_CR5","doi-asserted-by":"publisher","unstructured":"Rajkumar, S. V. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am. J. Hematol. https:\/\/doi.org\/10.1002\/ajh.25791 (2020).","DOI":"10.1002\/ajh.25791"},{"key":"1232_CR6","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1002\/ajh.24131","volume":"90","author":"N Majithia","year":"2015","unstructured":"Majithia, N. et al. Outcomes of primary refractory multiple myeloma and the impact of novel therapies. Am. J. Hematol. 90, 981\u2013985 (2015).","journal-title":"Am. J. Hematol."},{"key":"1232_CR7","doi-asserted-by":"publisher","unstructured":"Cohen, Y. C. et al. Primary failure of bortezomib in newly diagnosed multiple myeloma\u2014understanding the magnitude, predictors, and significance. Leuk. Lymphoma https:\/\/doi.org\/10.3109\/10428194.2015.1121258 (2016).","DOI":"10.3109\/10428194.2015.1121258"},{"key":"1232_CR8","doi-asserted-by":"publisher","unstructured":"Corre, J. et al. Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk. Haematologica https:\/\/doi.org\/10.3324\/haematol.2019.236588 (2019).","DOI":"10.3324\/haematol.2019.236588"},{"key":"1232_CR9","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/leu.2017.331","volume":"32","author":"SK Kumar","year":"2018","unstructured":"Kumar, S. K. et al. Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. Leukemia 32, 986\u2013995 (2018).","journal-title":"Leukemia"},{"key":"1232_CR10","doi-asserted-by":"publisher","unstructured":"Kastritis, E. et al. Early relapse post autologous transplant is associated with very poor survival and identifies an ultra high risk group of myeloma patients. Clin. Lymphoma Myeloma Leuk. https:\/\/doi.org\/10.1016\/j.clml.2019.10.014 (2020).","DOI":"10.1016\/j.clml.2019.10.014"},{"key":"1232_CR11","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ctrv.2010.08.008","volume":"37","author":"NWCJ van de Donk","year":"2011","unstructured":"van de Donk, N. W. C. J. et al. Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treatment Rev. 37, 266\u2013283 (2011).","journal-title":"Cancer Treatment Rev."},{"key":"1232_CR12","doi-asserted-by":"publisher","unstructured":"Wallington-Beddoe, C. T. & Coghlan, D. W. Resistance Mechanisms to Novel Therapies in Myeloma. in Update on Multiple Myeloma (ed., K. Ahmed Al-Anazi) (IntechOpen, 2019). https:\/\/doi.org\/10.5772\/intechopen.77004","DOI":"10.5772\/intechopen.77004"},{"key":"1232_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3892\/ijo.2016.3516","volume":"49","author":"SR Krishnan","year":"2016","unstructured":"Krishnan, S. R., Jaiswal, R., Brown, R. D., Luk, F. & Bebawy, M. Multiple myeloma and persistence of drug resistance in the age of novel drugs (Review). Int. J. Oncol. 49, 33\u201350 (2016).","journal-title":"Int. J. Oncol."},{"key":"1232_CR14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.drup.2014.12.001","volume":"18","author":"D Niewerth","year":"2015","unstructured":"Niewerth, D. et al. Molecular basis of resistance to proteasome inhibitors in hematological malignancies. Drug Resist. Update 18, 18\u201335 (2015).","journal-title":"Drug Resist. Update"},{"key":"1232_CR15","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/s41375-018-0362-z","volume":"33","author":"T Harding","year":"2019","unstructured":"Harding, T., Baughn, L. & Kumar, S. & Van Ness, B. The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies. Leukemia 33, 863\u2013883 (2019).","journal-title":"Leukemia"},{"key":"1232_CR16","doi-asserted-by":"crossref","unstructured":"Papadas, A. & Asimakopoulos, F. Mechanisms of Resistance in Multiple Myeloma. Handb. Exp. Pharmacol. 249, 251\u2013288 (Springer, 2018).","DOI":"10.1007\/164_2017_10"},{"key":"1232_CR17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1136\/jclinpath-2015-203414","volume":"69","author":"N Nikesitch","year":"2016","unstructured":"Nikesitch, N. & Ling, S. C. W. Molecular mechanisms in multiple myeloma drug resistance. J. Clin. Pathol. 69, 97\u2013101 (2016).","journal-title":"J. Clin. Pathol"},{"key":"1232_CR18","doi-asserted-by":"publisher","first-page":"100663","DOI":"10.1016\/j.drup.2019.100663","volume":"48","author":"S Narayanan","year":"2020","unstructured":"Narayanan, S. et al. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. Drug Resist. Update 48, 100663 (2020).","journal-title":"Drug Resist. Update"},{"key":"1232_CR19","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1158\/1535-7163.MCT-12-0782","volume":"12","author":"L Vincenz","year":"2013","unstructured":"Vincenz, L., J\u00e4ger, R., O\u2019Dwyer, M. & Samali, A. Endoplasmic reticulum stress and the unfolded protein response: targeting the Achilles heel of multiple myeloma. Mol. Cancer Therapeut. 12, 831\u2013843 (2013).","journal-title":"Mol. Cancer Therapeut."},{"key":"1232_CR20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3324\/haematol.2011.043331","volume":"97","author":"SCW Ling","year":"2012","unstructured":"Ling, S. C. W. et al. Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. Haematologica 97, 64\u201372 (2012).","journal-title":"Haematologica"},{"key":"1232_CR21","doi-asserted-by":"publisher","unstructured":"Klein, A. M. & Treutlein, B. Single cell analyses of development in the modern era. Development https:\/\/doi.org\/10.1242\/dev.181396 (2019).","DOI":"10.1242\/dev.181396"},{"key":"1232_CR22","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/s41591-018-0269-2","volume":"24","author":"G Ledergor","year":"2018","unstructured":"Ledergor, G. et al. Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. Nat. Med. 24, 1867\u20131876 (2018).","journal-title":"Nat. Med."},{"key":"1232_CR23","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/imr.12233","volume":"263","author":"Y Kawano","year":"2015","unstructured":"Kawano, Y. et al. Targeting the bone marrow microenvironment in multiple myeloma. Immunol. Rev. 263, 160\u2013172 (2015).","journal-title":"Immunol. Rev."},{"key":"1232_CR24","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.cell.2018.09.009","volume":"175","author":"M Cohen","year":"2018","unstructured":"Cohen, M. et al. Lung single-cell signaling interaction map reveals basophil role in macrophage imprinting. Cell 175, 1031\u20131044.e18 (2018).","journal-title":"Cell"},{"key":"1232_CR25","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1126\/science.aao4277","volume":"358","author":"C Medaglia","year":"2017","unstructured":"Medaglia, C. et al. Spatial reconstruction of immune niches by combining photoactivatable reporters and scRNA-seq. Science 358, 1622\u20131626 (2017).","journal-title":"Science"},{"key":"1232_CR26","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s13059-019-1812-2","volume":"20","author":"Y Baran","year":"2019","unstructured":"Baran, Y. et al. MetaCell: analysis of single-cell RNA-seq data using K-nn graph partitions. Genome Biol. 20, 206 (2019).","journal-title":"Genome Biol."},{"key":"1232_CR27","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","volume":"106","author":"PL Bergsagel","year":"2005","unstructured":"Bergsagel, P. L. et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106, 296\u2013303 (2005).","journal-title":"Blood"},{"key":"1232_CR28","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","volume":"108","author":"F Zhan","year":"2006","unstructured":"Zhan, F. et al. The molecular classification of multiple myeloma. Blood 108, 2020\u20132028 (2006).","journal-title":"Blood"},{"key":"1232_CR29","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.3324\/haematol.2015.124651","volume":"100","author":"R Khan","year":"2015","unstructured":"Khan, R. et al. Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG s0120). Haematologica 100, 1214\u20131221 (2015).","journal-title":"Haematologica"},{"key":"1232_CR30","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.1200\/JCO.2007.13.8545","volume":"26","author":"O Decaux","year":"2008","unstructured":"Decaux, O. et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du My\u00e9lome. J. Clin. Oncol. 26, 4798\u20134805 (2008).","journal-title":"J. Clin. Oncol."},{"key":"1232_CR31","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","volume":"109","author":"JD Shaughnessy","year":"2007","unstructured":"Shaughnessy, J. D. et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109, 2276\u20132284 (2007).","journal-title":"Blood"},{"key":"1232_CR32","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1182\/blood-2010-12-328252","volume":"118","author":"JD Shaughnessy","year":"2011","unstructured":"Shaughnessy, J. D. et al. Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with total therapy 3. Blood 118, 3512\u20133524 (2011).","journal-title":"Blood"},{"key":"1232_CR33","doi-asserted-by":"publisher","first-page":"8000","DOI":"10.1200\/JCO.2017.35.15_suppl.8000","volume":"35","author":"AJ Jakubowiak","year":"2017","unstructured":"Jakubowiak, A. J. et al. Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): an open-label, phase 1b study. J. Clin. Oncol. 35, 8000 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1232_CR34","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1182\/blood-2018-99-114311","volume":"132","author":"O Landgren","year":"2018","unstructured":"Landgren, O. et al. Bone marrow-based and longitudinal blood-based MRD tracking in newly diagnosed multiple myeloma patients treated with daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd): a correlative and clinical phase II study. Blood 132, 3281 (2018).","journal-title":"Blood"},{"key":"1232_CR35","first-page":"3110","volume":"130","author":"A Chari","year":"2017","unstructured":"Chari, A. et al. Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients with newly diagnosed multiple myeloma (MMY1001): updated results from an open-label, phase 1b study. Blood 130, 3110 (2017).","journal-title":"Blood"},{"key":"1232_CR36","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","volume":"9","author":"NWCJ Van De Donk","year":"2018","unstructured":"Van De Donk, N. W. C. J. & Usmani, S. Z. CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance. Front. Immunol. 9, 2134 (2018).","journal-title":"Front. Immunol."},{"key":"1232_CR37","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","volume":"128","author":"J Krejcik","year":"2016","unstructured":"Krejcik, J. et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 128, 384\u2013394 (2016).","journal-title":"Blood"},{"key":"1232_CR38","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","volume":"70","author":"P Robak","year":"2018","unstructured":"Robak, P., Drozdz, I., Szemraj, J. & Robak, T. Drug resistance in multiple myeloma. Cancer Treat. Rev. 70, 199\u2013208 (2018).","journal-title":"Cancer Treat. Rev."},{"key":"1232_CR39","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s41589-019-0291-9","volume":"15","author":"P Tsvetkov","year":"2019","unstructured":"Tsvetkov, P. et al. Mitochondrial metabolism promotes adaptation to proteotoxic stress. Nat. Chem. Biol. 15, 681\u2013689 (2019).","journal-title":"Nat. Chem. Biol."},{"key":"1232_CR40","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/nature10762","volume":"481","author":"M Greaves","year":"2012","unstructured":"Greaves, M. & Maley, C. C. Clonal evolution in cancer. Nature 481, 306\u2013313 (2012).","journal-title":"Nature"},{"key":"1232_CR41","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","volume":"120","author":"JJ Keats","year":"2012","unstructured":"Keats, J. J. et al. Clonal competition with alternating dominance in multiple myeloma. Blood 120, 1067\u20131076 (2012).","journal-title":"Blood"},{"key":"1232_CR42","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood.2018880930","volume":"134","author":"WH Khoo","year":"2019","unstructured":"Khoo, W. H. et al. A niche-dependent myeloid transcriptome signature defines dormant myeloma cells. Blood 134, 30\u201343 (2019).","journal-title":"Blood"},{"key":"1232_CR43","doi-asserted-by":"publisher","first-page":"e888","DOI":"10.1038\/cddis.2013.410","volume":"4","author":"P Nigro","year":"2013","unstructured":"Nigro, P., Pompilio, G. & Capogrossi, M. C. Cyclophilin A: a key player for human disease. Cell Death Dis. 4, e888\u2013e888 (2013).","journal-title":"Cell Death Dis."},{"key":"1232_CR44","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.1158\/0008-5472.CAN-06-1759","volume":"67","author":"JC Kyu","year":"2007","unstructured":"Kyu, J. C. et al. Overexpressed cyclophilin A in cancer cells renders resistance to hypoxia- and cisplatin-induced cell death. Cancer Res. 67, 3654\u20133662 (2007).","journal-title":"Cancer Res."},{"key":"1232_CR45","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","volume":"47","author":"S Matsuda","year":"2000","unstructured":"Matsuda, S. & Koyasu, S. Mechanisms of action of cyclosporine. Immunopharmacology 47, 119\u2013125 (2000).","journal-title":"Immunopharmacology"},{"key":"1232_CR46","doi-asserted-by":"crossref","unstructured":"Nikesitch, N., Lee, J. M., Ling, S. & Roberts, T. L. Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance. Clin. Transl. Immunol. 7, e1007 (2018).","DOI":"10.1002\/cti2.1007"},{"key":"1232_CR47","doi-asserted-by":"crossref","unstructured":"Lee, J. & Kim, S. S. An overview of cyclophilins in human cancers. J. Int. Med. Res. 38, 1561\u20131574 (2010).","DOI":"10.1177\/147323001003800501"},{"key":"1232_CR48","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1126\/science.1247651","volume":"343","author":"DA Jaitin","year":"2014","unstructured":"Jaitin, D. A. et al. Massively parallel single-cell RNA-seq for marker-free decomposition of tissues into cell types. Science 343, 776\u2013779 (2014).","journal-title":"Science"},{"key":"1232_CR49","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/j.cell.2015.11.013","volume":"163","author":"F Paul","year":"2015","unstructured":"Paul, F. et al. Transcriptional heterogeneity and lineage commitment in myeloid progenitors. Cell 163, 1663\u20131677 (2015).","journal-title":"Cell"},{"key":"1232_CR50","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","volume":"169","author":"H Keren-Shaul","year":"2017","unstructured":"Keren-Shaul, H. et al. A unique microglia type associated with restricting development of Alzheimer\u2019s disease. Cell 169, 1276\u20131290.e17 (2017).","journal-title":"Cell"},{"key":"1232_CR51","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1006\/mthe.2000.0103","volume":"2","author":"N Klages","year":"2000","unstructured":"Klages, N., Zufferey, R. & Trono, D. A stable system for the high-titer production of multiply attenuated lentiviral vectors. Mol. Ther. 2, 170\u2013176 (2000).","journal-title":"Mol. Ther."},{"key":"1232_CR52","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17, e328\u2013e346 (2016).","journal-title":"Lancet Oncol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01232-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01232-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01232-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T00:10:19Z","timestamp":1650240619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01232-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,22]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["1232"],"URL":"https:\/\/doi.org\/10.1038\/s41591-021-01232-w","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,22]]},"assertion":[{"value":"16 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The clinical trial was an investigator-initiated study (IIS); as such, Y.C. acted as sponsor for the study. The IIS was approved by Amgen, who provided funding and supply of the clinical drug CFZ. Y.C. is a consultant for Janssen, Amgen, Neopharm, Takeda and Madison. A patent application has been filed related to this work. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}